Literature DB >> 29278600

Ovarian Cancer Prevention, Screening, and Early Detection: Report From the 11th Biennial Ovarian Cancer Research Symposium.

Jeremy Chien, Elizabeth M Poole.   

Abstract

OBJECTIVE: The aim of this study is to provide a summary report on recent research advances in ovarian cancer prevention, screening, and early detection that were presented at the 11th Biennial Ovarian Cancer Research Symposium in Seattle, Wash.
METHODS: At the symposium, researchers from around the world participated in the poster, invited oral presentation and keynote presentation, and discussed the latest advances in the areas of cancer prevention, screening, and early detection.
RESULTS: In the Scientific Session for Prevention, Screening, and Early Detection, Usha Menon, PhD (University of College London), presented exploratory studies from the ongoing UK Collaborative Trial of Ovarian Cancer Screening trial. Karen Lu, MD, presented her studies on BRCA testing and salpingectomies as prevention strategies. Eight speakers were selected from the abstracts for short oral presentations, and the topic ranges from Ovarian Cancer Early Detection Program by Saul Rivkin, MD, to the ultra-deep sequencing of somatic mutations in TP53 in normal and cancer patients by Rosana Risques, PhD. Fourteen additional poster presentations, ranging from the potential role of cancer stem cells in recurrence to retrotransposons in ovarian cancer development, round up the session.
CONCLUSIONS: Although progress is being made in the areas of prevention, screening, and early detection, these advances have not yet translated into tangible clinical benefits for patients with ovarian cancer. A wide array of research topics presented in the session provides a glimmer of hope that better understanding of genetic risk factors, refining screening strategies, and developing new methods for early detection will eventually lead to improved outcome for patients with ovarian cancer.

Entities:  

Mesh:

Year:  2017        PMID: 29278600      PMCID: PMC6154781          DOI: 10.1097/IGC.0000000000001118

Source DB:  PubMed          Journal:  Int J Gynecol Cancer        ISSN: 1048-891X            Impact factor:   3.437


  10 in total

1.  Newly diagnosed and relapsed epithelial ovarian carcinoma: ESMO Clinical Practice Guidelines for diagnosis, treatment and follow-up.

Authors:  J A Ledermann; F A Raja; C Fotopoulou; A Gonzalez-Martin; N Colombo; C Sessa
Journal:  Ann Oncol       Date:  2013-10       Impact factor: 32.976

Review 2.  Ovarian cancer.

Authors:  Gordon C Jayson; Elise C Kohn; Henry C Kitchener; Jonathan A Ledermann
Journal:  Lancet       Date:  2014-04-21       Impact factor: 79.321

3.  Screening for ovarian cancer: U.S. Preventive Services Task Force reaffirmation recommendation statement.

Authors:  Virginia A Moyer
Journal:  Ann Intern Med       Date:  2012-12-18       Impact factor: 25.391

4.  Preventing future cancers by testing women with ovarian cancer for BRCA mutations.

Authors:  Janice S Kwon; Molly S Daniels; Charlotte C Sun; Karen H Lu
Journal:  J Clin Oncol       Date:  2009-10-19       Impact factor: 44.544

5.  A randomized study of screening for ovarian cancer: a multicenter study in Japan.

Authors:  H Kobayashi; Y Yamada; T Sado; M Sakata; S Yoshida; R Kawaguchi; S Kanayama; H Shigetomi; S Haruta; Y Tsuji; S Ueda; T Kitanaka
Journal:  Int J Gynecol Cancer       Date:  2007-07-21       Impact factor: 3.437

6.  Integrated genomic analyses of ovarian carcinoma.

Authors: 
Journal:  Nature       Date:  2011-06-29       Impact factor: 49.962

7.  Driver mutations in TP53 are ubiquitous in high grade serous carcinoma of the ovary.

Authors:  Ahmed Ashour Ahmed; Dariush Etemadmoghadam; Jillian Temple; Andy G Lynch; Mohamed Riad; Raghwa Sharma; Colin Stewart; Sian Fereday; Carlos Caldas; Anna Defazio; David Bowtell; James D Brenton
Journal:  J Pathol       Date:  2010-05       Impact factor: 7.996

8.  Effect of screening on ovarian cancer mortality: the Prostate, Lung, Colorectal and Ovarian (PLCO) Cancer Screening Randomized Controlled Trial.

Authors:  Saundra S Buys; Edward Partridge; Amanda Black; Christine C Johnson; Lois Lamerato; Claudine Isaacs; Douglas J Reding; Robert T Greenlee; Lance A Yokochi; Bruce Kessel; E David Crawford; Timothy R Church; Gerald L Andriole; Joel L Weissfeld; Mona N Fouad; David Chia; Barbara O'Brien; Lawrence R Ragard; Jonathan D Clapp; Joshua M Rathmell; Thomas L Riley; Patricia Hartge; Paul F Pinsky; Claire S Zhu; Grant Izmirlian; Barnett S Kramer; Anthony B Miller; Jian-Lun Xu; Philip C Prorok; John K Gohagan; Christine D Berg
Journal:  JAMA       Date:  2011-06-08       Impact factor: 157.335

9.  Clinical Use of Cancer Biomarkers in Epithelial Ovarian Cancer: Updated Guidelines From the European Group on Tumor Markers.

Authors:  György Sölétormos; Michael J Duffy; Suher Othman Abu Hassan; René H M Verheijen; Bengt Tholander; Robert C Bast; Katja N Gaarenstroom; Catharine M Sturgeon; Johannes M Bonfrer; Per Hyltoft Petersen; Hugo Troonen; Gian CarloTorre; Jan Kanty Kulpa; Malgorzata K Tuxen; Raphael Molina
Journal:  Int J Gynecol Cancer       Date:  2016-01       Impact factor: 3.437

10.  Ovarian cancer screening and mortality in the UK Collaborative Trial of Ovarian Cancer Screening (UKCTOCS): a randomised controlled trial.

Authors:  Ian J Jacobs; Usha Menon; Andy Ryan; Aleksandra Gentry-Maharaj; Matthew Burnell; Jatinderpal K Kalsi; Nazar N Amso; Sophia Apostolidou; Elizabeth Benjamin; Derek Cruickshank; Danielle N Crump; Susan K Davies; Anne Dawnay; Stephen Dobbs; Gwendolen Fletcher; Jeremy Ford; Keith Godfrey; Richard Gunu; Mariam Habib; Rachel Hallett; Jonathan Herod; Howard Jenkins; Chloe Karpinskyj; Simon Leeson; Sara J Lewis; William R Liston; Alberto Lopes; Tim Mould; John Murdoch; David Oram; Dustin J Rabideau; Karina Reynolds; Ian Scott; Mourad W Seif; Aarti Sharma; Naveena Singh; Julie Taylor; Fiona Warburton; Martin Widschwendter; Karin Williamson; Robert Woolas; Lesley Fallowfield; Alistair J McGuire; Stuart Campbell; Mahesh Parmar; Steven J Skates
Journal:  Lancet       Date:  2015-12-17       Impact factor: 79.321

  10 in total
  17 in total

1.  The influence of birth cohort and calendar period on global trends in ovarian cancer incidence.

Authors:  Citadel J Cabasag; Melina Arnold; John Butler; Manami Inoue; Britton Trabert; Penelope M Webb; Freddie Bray; Isabelle Soerjomataram
Journal:  Int J Cancer       Date:  2019-04-30       Impact factor: 7.396

Review 2.  Quercetin: a natural compound for ovarian cancer treatment.

Authors:  Rana Shafabakhsh; Zatollah Asemi
Journal:  J Ovarian Res       Date:  2019-06-15       Impact factor: 4.234

3.  A comprehensive analysis of somatic alterations in Chinese ovarian cancer patients.

Authors:  Yingli Zhang; Xiaoliang Shi; Jiejie Zhang; Xi Chen; Peng Zhang; Angen Liu; Tao Zhu
Journal:  Sci Rep       Date:  2021-01-11       Impact factor: 4.379

4.  IL-17 Affects the Progression, Metastasis, and Recurrence of Laryngeal Cancer via the Inhibition of Apoptosis through Activation of the PI3K/AKT/FAS/FASL Pathways.

Authors:  Yang Song; Ming Yang; Hongjian Zhang; Yan Sun; Ye Tao; Huihui Li; Jing Zhang; Yuncheng Li; Jianming Yang
Journal:  J Immunol Res       Date:  2020-12-18       Impact factor: 4.818

5.  The Overexpression of Acyl-CoA Medium-Chain Synthetase-3 (ACSM3) Suppresses the Ovarian Cancer Progression via the Inhibition of Integrin β1/AKT Signaling Pathway.

Authors:  Limei Yan; Zeping He; Wei Li; Ning Liu; Song Gao
Journal:  Front Oncol       Date:  2021-03-31       Impact factor: 6.244

Review 6.  miRNAs as Biomarkers in Disease: Latest Findings Regarding Their Role in Diagnosis and Prognosis.

Authors:  Carmen Elena Condrat; Dana Claudia Thompson; Madalina Gabriela Barbu; Oana Larisa Bugnar; Andreea Boboc; Dragos Cretoiu; Nicolae Suciu; Sanda Maria Cretoiu; Silviu Cristian Voinea
Journal:  Cells       Date:  2020-01-23       Impact factor: 6.600

7.  Relationship between inter-α-trypsin inhibitor heavy chain 4 and ovarian cancer.

Authors:  Min Huang; Wei Zhang; Bingbing Zhao; Li Li
Journal:  Chin J Cancer Res       Date:  2019-12       Impact factor: 5.087

8.  ZNF703 promotes tumor progression in ovarian cancer by interacting with HE4 and epigenetically regulating PEA15.

Authors:  Shuang Wang; Caixia Wang; Yuexin Hu; Xiao Li; Shan Jin; Ouxuan Liu; Rui Gou; Yuan Zhuang; Qian Guo; Xin Nie; Liancheng Zhu; Juanjuan Liu; Bei Lin
Journal:  J Exp Clin Cancer Res       Date:  2020-11-27

9.  Free CA125 promotes ovarian cancer cell migration and tumor metastasis by binding Mesothelin to reduce DKK1 expression and activate the SGK3/FOXO3 pathway.

Authors:  Qianyu Huo; Chen Xu; Yanhong Shao; Qin Yu; Lunhui Huang; Yunde Liu; Huijing Bao
Journal:  Int J Biol Sci       Date:  2021-01-14       Impact factor: 6.580

Review 10.  Quantitative Mass Spectrometry-Based Proteomics for Biomarker Development in Ovarian Cancer.

Authors:  Joohyun Ryu; Stefani N Thomas
Journal:  Molecules       Date:  2021-05-03       Impact factor: 4.411

View more

北京卡尤迪生物科技股份有限公司 © 2022-2023.